The Role of mTORC1 Pathway and Autophagy in Resistance to Platinum-Based Chemotherapeutics.
Int J Mol Sci
; 24(13)2023 Jun 26.
Article
em En
| MEDLINE
| ID: mdl-37445831
ABSTRACT
Cisplatin (cis-diamminedichloroplatinum I) is a platinum-based drug, the mainstay of anticancer treatment for numerous solid tumors. Since its approval by the FDA in 1978, the drug has continued to be used for the treatment of half of epithelial cancers. However, resistance to cisplatin represents a major obstacle during anticancer therapy. Here, we review recent findings on how the mTORC1 pathway and autophagy can influence cisplatin sensitivity and resistance and how these data can be applicable for the development of new therapeutic strategies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article